Management of Pulmonary Embolism-Induced Cardiac Arrest

Thrombolytic Therapy

The European Society of Cardiology recommends a tissue plasminogen activator (tPA) dose of 0.6 mg/kg (maximum 50 mg) administered as a rapid infusion over 15 minutes for PE-induced cardiac arrest, with alternative thrombolytic agents such as streptokinase and urokinase considered if tPA is unavailable 1, 2
The accelerated regimen of 0.6 mg/kg tPA over 15 minutes is recommended for extreme hemodynamic instability such as cardiac arrest 1

Absolute contraindications to thrombolysis include history of hemorrhagic stroke or stroke of unknown origin, ischemic stroke in previous 6 months, central nervous system neoplasm, major trauma, surgery, or head injury in previous 3 weeks, and active bleeding, although many contraindications become relative in the setting of cardiac arrest due to PE 1, 3
Contraindications to thrombolytic therapy also include uncontrolled severe hypertension, defined as systolic pressure >180 mmHg and diastolic pressure >110 mmHg 4

The American Heart Association recommends maintaining blood pressure below 180/110 mmHg after tPA infusion for massive pulmonary embolism to minimize the risk of bleeding complications while ensuring adequate tissue perfusion 5
First-line treatment for blood pressure management is Labetalol 10 mg IV followed by continuous IV infusion 2-8 mg/min, or alternative Nicardipine IV 5 mg/hr, titrate up by 2.5 mg/hr every 5-15 minutes, maximum 15 mg/hr 5
Monitor blood pressure every 15 minutes for the first 2 hours after starting tPA, then every 30 minutes for the next 6 hours, and then hourly for the next 16 hours 5

Severe bleeding occurs in approximately 14% of patients receiving thrombolytic therapy for PE, with intracranial bleeding occurring in about 1.9% of these patients 4
Monitor for signs of improving right ventricular function, which typically occurs within hours of successful thrombolysis, with a significant reduction in mean RV end-diastolic area documented as early as 3 hours after tPA treatment 3
Avoid concomitant antiplatelet drugs in the first 24 hours after thrombolysis, and avoid excessive BP lowering in patients with residual right ventricular dysfunction 6, 5
Careful fluid management is essential, as excessive fluid administration can worsen right ventricular distension in patients with PE, and monitor for bleeding complications at all access sites, particularly if invasive procedures were performed prior to thrombolysis 5, 4